137419-24-0Relevant articles and documents
Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2
Chen, Xiaoqi,Mihalic, Jeff,Fan, Pingchen,Liang, Lingming,Lindstrom, Michelle,Wong, Sylvia,Ye, Qiuping,Fu, Ying,Jaen, Juan,Chen, Jin-Long,Dai, Kang,Li, Leping
, p. 363 - 366 (2012)
A series of spiropiperidine carbazoles were synthesized and evaluated as MCHR2 antagonists using a FLIPR assay. The pharmacokinetic properties of selected compounds have also been studied. This effort led to the discovery of potent and specific MCHR2 antagonists. Compound 38 demonstrated good pharmacokinetic properties across rat, beagle dog and rhesus monkey and had a favorable selectivity profile against a number of other receptors. These MCHR2 antagonists are considered appropriate tool compounds for study of the function of MCHR2 in vivo.
A class of GPR40 agonist compounds with amide structure, and uses thereof
-
Paragraph 0173; 0174; 0176, (2019/05/02)
The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.
Compound as potassium channel modulator
-
Paragraph 1093; 1095; 1096; 1097, (2018/07/30)
The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.